ReviewWorld journal of gastroenterology2014
Pancreatic cancer organotypics: High throughput, preclinical models for pharmacological agent evaluation.
Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 43 citations in OpenAlex.
- Mapping Tumor-Stroma-ECM Interactions in Spatially Advanced 3D Models of Pancreatic Cancer.ACS applied materials & interfaces · 2025Article
- Systems Genome: Coordinated Gene Activity Networks, Recurring Coordination Modules, and Genome Homeostasis in Developing Neurons.International journal of molecular sciences · 2024Article
- Pancreatic cancer orthotopic graft in a murine model.Acta cirurgica brasileira · 2023Article
- 3D Bioprinted cancer models: Revolutionizing personalized cancer therapy.Translational oncology · 2021Review
- Photodestruction of Stromal Fibroblasts Enhances Tumor Response to PDT in 3D Pancreatic Cancer Coculture Models.Photochemistry and photobiology · 2021Article
- Modeling human pancreatic ductal adenocarcinoma for translational research: current options, challenges, and prospective directions.Annals of pancreatic cancer · 2020Article
- Preclinical mouse models for immunotherapeutic and non-immunotherapeutic drug development for pancreatic ductal adenocarcinoma.Annals of pancreatic cancer · 2020Article
- Pseudopterosin andBioengineering (Basel, Switzerland) · 2020Article
- Review
- The A818-6 system as an in-vitro model for studying the role of the transportome in pancreatic cancer.BMC cancer · 2020Article
- 3D approaches to model the tumor microenvironment of pancreatic cancer.Theranostics · 2020Review
- Organotypic Modeling of the Tumor Landscape.Frontiers in cell and developmental biology · 2020Review
- Chemoradiotherapy screening in a novel biomimetic polymer based pancreatic cancer model.RSC advances · 2019Article
- Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma.The Journal of pathology · 2019Article
- Ex vivo organotypic culture system of precision-cut slices of human pancreatic ductal adenocarcinoma.Scientific reports · 2019Article
- Review
- Sensitisation to mitoxantrone-induced apoptosis by the oncolytic adenovirus Ad∆∆ through Bcl-2-dependent attenuation of autophagy.Oncogenesis · 2018Article
- Patient-derived organoid models help define personalized management of gastrointestinal cancer.The British journal of surgery · 2018Review
- A novel microfluidic 3D platform for culturing pancreatic ductal adenocarcinoma cells: comparison with in vitro cultures and in vivo xenografts.Scientific reports · 2017Article
- Generation of an in vitro 3D PDAC stroma rich spheroid model.Biomaterials · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer carries a terrible prognosis, as the fourth most common cause of cancer death in the Western world. There is clearly a need for new therapies to treat this disease. One of the reasons no effective treatment has been developed in the past decade may in part, be explained by the diverse influences exerted by the tumour microenvironment. The tumour stroma cross-talk in pancreatic cancer can influence chemotherapy delivery and response rate. Thus, appropriate preclinical in vitro models which can bridge simple 2D in vitro cell based assays and complex in vivo models are required to understand the biology of pancreatic cancer. Here we discuss the evolution of 3D organotypic models, which recapitulare the morphological and functional features of pancreatic ductal adenocarcinoma (PDAC). Organotypic cultures are a valid high throughput preclinical in vitro model that maybe a useful tool to help establish new therapies for PDAC. A huge advantage of the organotypic model system is that any component of the model can be easily modulated in a short time-frame. This allows new therapies that can target the cancer, the stromal compartment or both to be tested in a model that mirrors the in vivo situation. A major challenge for the future is to expand the cellular composition of the organotypic model to further develop a system that mimics the PDAC environment more precisely. We discuss how this challenge is being met to increase our understanding of this terrible disease and develop novel therapies that can improve the prognosis for patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.